Antivirals interacting with hepatitis B virus core protein and core mutations may misdirect capsid assembly in a similar fashion

Biochemical Pharmacology

Volumn 66, Issue 12, 2003, Pages 2273-2279

  Hacker, Hans Jörg ^a   Deres, Karl ^b   Mildenberger, Maria ^a   Schröder, Claus H ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Antivirals; Capsid assembly; HBV core protein; Mammalian two hybrid system; Misdirection

Indexed keywords

ANTIVIRUS AGENT; APTAMER; CORE PROTEIN; DIMER; INTERFERON; MONOMER; NUCLEOSIDE ANALOG; OLIGOMER; PYRIMIDINE DERIVATIVE;

BINDING SITE; CHRONIC HEPATITIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SENSITIVITY; GENE REPLICATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; TRANSACTIVATION; TREATMENT OUTCOME; TWO HYBRID SYSTEM; VIRUS CAPSID; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0344585939     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.08.001     Document Type: Note

References (36)

1. Seeger C., Mason W.S. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64:2000;51-68.
2. Lamberts C., Nassal M., Velhagen I., Zentgraf H., Schröder C.H. Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis. J. Virol. 67:1993;3756-3762.
3. Zhou S., Standring D.N. Hepatitis B virus capsid particles are assembled from core-protein dimer precursors. Proc. Natl. Acad. Sci. U.S.A. 89:1992;10046-10050.
4. Seifer M., Zhou S., Standring D.N. A micromolar pool of antigenically distinct precursors is required to initiate cooperative assembly of hepatitis B virus capsids in Xenopus oocytes. J. Virol. 67:1993;249-257.
5. Wynne S.A., Crowther R.A., Leslie A.G. The crystal structure of the human hepatitis B virus capsid. Mol. Cell. 3:1999;771-780.
6. Seifer M., Standring D.N. Assembly and antigenicity of hepatitis B virus core particles. Intervirology. 38:1995;47-62.
7. Ehrlich L.S., Agresta B.E., Carter C.A. Assembly of recombinant human immunodeficiency virus type 1 capsid protein in vitro. J. Virol. 66:1992;4874-4883.
8. Zlotnick A., Johnson J.M., Wingfield P.W., Stahl S.J., Endres D. A theoretical model successfully identifies features of hepatitis B virus capsid assembly. Biochemistry. 38:1999;14644-14652.
9. Ceres P., Zlotnick A. Weak protein-protein interactions are sufficient to drive assembly of hepatitis B virus capsids. Biochemistry. 41:2002;11525-11531.
10. Lingappa J.R., Martin R.L., Wong M.L., Ganem D., Welch W.J., Lingappa V.R. A eukaryotic cytosolic chaperonin is associated with a high molecular weight intermediate in the assembly of hepatitis B virus capsid, a multimeric particle. J. Cell Biol. 125:1994;99-111.
11. Bartenschlager R., Schaller H. Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J. 11:1992;3413-3420.
12. Von Weizsacker F., Kock J., Wieland S., Beck J., Nassal M., Blum H.E. cis-preferential recruitment of duck hepatitis B virus core protein to the RNA/polymerase preassembly complex. Hepatology. 35:2002;209-216.
13. König S., Beterams G., Nassal M. Mapping of homologous interaction sites in the hepatitis B virus core protein. J. Virol. 72:1998;4997-5005.
14. Watts N.R., Conway J.F., Cheng N., Stahl S.J., Belnap D.M., Steven A.C., Wingfield P.T. The morphogenic linker peptide of HBV capsid protein forms a mobile array on the interior surface. EMBO J. 21:2002;876-884.
15. Chang C., Zhou S., Ganem D., Standring D.N. Phenotypic mixing between different hepadnavirus nucleocapsid proteins reveals C protein dimerization to be cis preferential. J. Virol. 68:1994;5225-5231.
16. Fearon E.R., Finkel T., Gillison M.L., Kennedy S.P., Casella J.F., Tomaselli G.F., Morrow J.S., Van Dang C. Karyoplasmic interaction selection strategy: a general strategy to detect protein-protein interactions in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 89:1992;7958-7962.
17. Marmorstein R., Carey M., Ptashne M., Harrison S.C. DNA recognition by GAL4: structure of a protein-DNA complex. Nature. 356:1992;408-414.
18. Nicholls C.D., McLure K.G., Shields M.A., Lee P.W. Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect. J. Biol. Chem. 277:2002;12937-12945.
19. Yeh C.T., Liaw Y.F., Ou J.H. The arginine-rich domain of hepatitis B virus precore and core proteins contains a signal for nuclear transport. J. Virol. 64:1990;6141-6147.
20. Eckhardt S.G., Milich D.R., McLachlan A. Hepatitis B virus core antigen has two nuclear localization sequences in the arginine-rich carboxyl terminus. J. Virol. 65:1991;575-582.
21. Aiba N., McGarvey M.J., Waters J., Hadziyannis S.J., Thomas H.C., Karayiannis P. The precore sequence of hepatitis B virus is required for nuclear localization of the core protein. Hepatology. 26:1997;1311-1317.
22. Nassal M. Novel molecular approaches toward therapy of chronic hepatitis B. Arch. Virol. 142:1997;611-628.
23. Zoulim F. Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models. Antivir. Chem. Chemother. 12(Suppl. 1):2001;131-142.
24. Scaglioni P.P., Melegari M., Wands J.R. Posttranscriptional regulation of hepatitis B virus replication by the precore protein. J. Virol. 71:1997;345-353.
25. Yamamoto M., Hayashi N., Takehara T., Ueda K., Mita E., Tatsumi T., Sasaki Y., Kasahara A., Hori M. Intracellular single-chain antibody against hepatitis B virus core protein inhibits the replication of hepatitis B virus in cultured cells. Hepatology. 30:1999;300-307.
26. Butz K., Denk C., Fitscher B., Crnkovic-Mertens I., Ullmann A., Schröder C.H., Hoppe-Seyler F. Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity. Oncogene. 20:2001;6579-6586.
27. Mehta A., Conyers B., Tyrrell D.L., Walters K.A., Tipples G.A., Dwek R.A., Block T.M. Structure-activity relationship of a new class of anti-hepatitis B virus agents. Antimicrob. Agents Chemother. 46:2002;4004-4008.
28. Zlotnick A., Ceres P., Singh S., Johnson J.M. A small molecule inhibits and misdirects assembly of hepatitis B virus capsids. J. Virol. 76:2002;4848-4854.
29. Deres K., Schröder C.H., Paessens A., Goldmann S., Hacker H.J., Weber O., Kramer T., Niewöhner U., Pleiss U., Stoltefuss J., Graef E., Koletzki D., Masantschek R.N., Reimann A., Jaeger R., Gross R., Beckermann B., Schlemmer K.H., Haebich D., Rübsamen-Waigmann H. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science. 299:2003;893-896.
30. Ulrich R., Nassal M., Meisel H., Krüger D.H. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv. Virus Res. 50:1998;141-182.
31. Yamaguchi M., Miyatsu Y., Mizokami H., Matsuoka L., Takeo K. Translocation of hepatitis B virus core particles through nuclear pores in transformed yeast cells. J. Electron Microsc. (Tokyo). 45:1996;321-324.
32. Panté N., Kann M. Nuclear pore complex is able to transport macromolecules with diameters of about 39 nm. Mol. Biol. Cell. 13:2002;425-434.
33. Leung S., Miyake H., Zellweger T., Tolcher A., Gleave M.E. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int. J. Cancer. 91:2001;846-850.
34. Vidal M., Legrain P. Yeast forward and reverse 'n'-hybrid systems. Nucleic Acids Res. 27:1999;919-929.
35. Chen C., Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell Biol. 7:1987;2745-2752.
36. Hilger C., Velhagen I., Zentgraf H., Schroder C.H. Diversity of hepatitis B virus X gene-related transcripts in hepatocellular carcinoma: a novel polyadenylation site on viral DNA. J. Virol. 65:1991;4284-4291.